LUMASON
PeakNDAINTRAVENOUSFOR SUSPENSION
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
4/8 — Partial
LUMASON by Bracco is blood, the acoustic impedance of lumason microspheres is lower than that of the surrounding non-aqueous tissue. First approved in 2014.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMASON is an intravenous ultrasound contrast agent containing sulfur hexafluoride microbubbles that enhance visualization during ultrasound imaging procedures. It works by reflecting ultrasound waves to improve image quality and diagnostic accuracy. The product is indicated for contrast-enhanced ultrasound imaging across multiple organ systems.
Peak12.5 years to LOE
LUMASON is in peak commercial phase with established market presence, likely supporting a stable commercial team focused on market optimization.
Mechanism of Action
blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Lumason® Infusion vs. Bolus Administrations
Started Jul 2024
106 enrolled
Heart Diseases
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Started Oct 2015
174 enrolled
Coronary Artery Disease
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Started Oct 2015
13 enrolled
Heart Disease
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Started Sep 2015
175 enrolled
Coronary Artery Disease
Worked on LUMASON at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.